Study achieved key objectives for safety, efficacy and pharmacokinetics After completion of the study, all patients enrolled in an extension study pegunigalsidase alfa (PRX-102) provided coverage to patients for the entire 4-week period in treated patients No new patients developed
Anticipated PDUFA for PRX-102 in Fabry disease currently set for April 27, 2021 Company, with its Commercialization Partner, Chiesi, poised to commercialize PRX-102 Additional data and milestones expected throughout 2021 CARMIEL, Israel , Feb. 18, 2021 /PRNewswire/ -- Protalix BioTherapeutics,
CARMIEL, Israel , Feb. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX) (the "Company"), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant
CARMIEL, Israel , Feb. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based
CARMIEL, Israel , Feb. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based
Phase III BRIDGE open-label, switch-over clinical trial met key objectives for safety and efficacy Mean overall annualized change in estimated Glomerular Filtration Rate (eGFR slope) improved from -5.9 to -1.2 mL/min/1.73 m2/year 12-months on-treatment Phase III BRIDGE study final results suggest a
Data to be presented in an oral presentation and a poster presentation CARMIEL, Israel , Feb. 1, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic
CARMIEL, Israel , Jan. 4, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based